Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 04/22/19
End: 05/20/19
Due: 05/20/20
Phase: N/A
Priority: Normal
Start: 07/06/20
End: 07/30/21
Due: 07/30/22
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Doravirine, Rifapentine and Isoniazid Interaction | NCT03886701 | Walter K. Kraft | user2@example.com | None | 2019-04-22 | 2019-05-20 | 2020-05-20 | - | - | 2025-07-14 |
| Sirolimus in COVID-19 Phase 1 | NCT04371640 | Walter K. Kraft | user2@example.com | None | 2020-07-06 | 2021-07-30 | 2022-07-30 | - | - | 2025-07-14 |